Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Arrowhead BID
$414.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hybrigenics SA's inecalcitol is designated as an orphan drug for chronic lymphocytic leukemia in Europe


Tuesday, 28 Jan 2014 12:00pm EST 

Hybrigenics SA:Announces the decision of the European Commission to designate inecalcitol as an orphan drug for the treatment of chronic lymphocytic leukemia (CLL), following the positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency.Says Inecalcitol is listed in the Community Register of designated Orphan Medicinal Products under the entry code EU/3/13/1223. 

Company Quote

1.6
0.0 +0.00%
11:23am EDT